BioStock: Immunicum updates clinical development strategy
Since bringing in Sven Rohmann as new CEO in August, Immunicum has updated its clinical development strategy to include four major pillars aimed at delineating the best way to market. In addition, the company presented positive preclinical data at ESMO 2020 last month, showing that the its off-the-shelf immuno-oncology treatment ilixadencel strengthens the efficacy of existing immunotherapies.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se